Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Portola Pharmaceuticals commences Phase 1 trial of PRT062607 for chronic inflammatory diseases

Portola Pharmaceuticals, Inc. today announced that it has initiated its first in human Phase 1 trial in healthy volunteers of PRT062607, a novel, oral Syk-specific kinase inhibitor in development to treat chronic inflammatory diseases, including rheumatoid arthritis (RA), and certain cancers, including non-Hodgkin's lymphoma and chronic lymphocytic leukemia. In preclinical in vivo models of RA, PRT062607 was shown to reduce inflammation in a dose-dependent manner.

23 Mar 2010

ReGear Life Sciences achieves preferred partner status with Genesis Rehab Services

ReGear Life Sciences, Inc. announces that it has been named a Preferred Partner to Genesis Rehab Services.

23 Mar 2010

Walgreens's fiscal 2010 second-quarter sales up 3.1% to $17.0 billion

Walgreens today announced earnings and sales for the second quarter of fiscal year 2010.

23 Mar 2010

Dual-energy CT helps diagnose gout reliably in acute, emergency settings

A medical imaging technique called dual-energy computed tomography (CT) is an effective and reliable way to diagnose gout in the acute, emergency setting, according to a study published in the April issue of the American Journal of Roentgenology. Dual-energy CT is an advanced medical imaging technique that can detect vessels and bones and display them in clear contrast to one another. It enables physicians to diagnose many patients' conditions faster and more accurately as it can better characterize tissue composition better than conventional CT.

23 Mar 2010

Can-Fite BioPharma files patent application for treatment of Uveitis with A3 adenosine receptor ligands

Can-Fite BioPharma Ltd, a biopharmaceutical company, traded on the TASE and developing anti- inflammatory and anti-cancer drugs, announced today the filing of a patent application, in conjunction with the United Stated National Institutes of Health (NIH), for the treatment of Uveitis with its A3 adenosine receptor ligands.

23 Mar 2010

ChemoCentryx undertakes Phase II clinical trial of CCX140

ChemoCentryx, Inc., today announced that it has undertaken a Phase II clinical trial of CCX140, a novel, orally-available small molecule compound designed to specifically target the chemokine receptor known as CCR2.

22 Mar 2010

AARDA launches campaign on family AQ

In honor of the designation of March as National Autoimmune Disease Awareness Month by the U.S. Senate on March 4, 2010, the American Autoimmune Related Diseases Association (AARDA) wants to help you learn your family's AQ. AQ is a play on IQ that stands for Autoimmune Quotient. It's about knowing how likely you or a loved one is to develop an autoimmune disease, based on the prevalence of these diseases and your family history. The campaign features AARDA National Spokesperson and Actress Kellie Martin, best known for her memorable roles on "E.R." and "Life Goes On."

22 Mar 2010

Portable ultrasound device to treat chronic joint pain from arthritis

In recent years, doctors have used ultrasound to effective treat joint pain from arthritis and other ailments without the use of drugs. The drawback to these treatments, however, is that they can only be administered in a doctor's office or clinic, since the ultrasound devices currently used are bulky and expensive.

20 Mar 2010

EUREKA project develops unique range of antibodies

EUREKA project E! 3424 RECAN has developed a range of unique and highly specific monoclonal and polyclonal antibodies - the proteins produced in the blood which counteract bacteria, viruses or cancerous cells.

20 Mar 2010

Effective defense against HIV: Acne drug minocycline

Johns Hopkins scientists have found that a safe and inexpensive antibiotic in use since the 1970s for treating acne effectively targets infected immune cells in which HIV, the virus that causes AIDS, lies dormant and prevents them from reactivating and replicating.

20 Mar 2010

Arthritis Foundation supports Congress’ efforts for meaningful health care reform

The Arthritis Foundation supports the efforts of Congress to enact meaningful health care reform to address the health care needs of the 46 million men, women and children with arthritis.

20 Mar 2010

Lexicon Pharmaceuticals completes public offering and concurrent private placement of common stock

Lexicon Pharmaceuticals, Inc. today announced the completion of its previously-announced public offering and concurrent private placement of its common stock, resulting in net proceeds to Lexicon of approximately $181.4 million after the exercise in full by the underwriters of their over-allotment option and by Invus, L.P., Lexicon's largest stockholder, of its associated right to purchase additional shares.

20 Mar 2010

BioTrends publishes new LaunchTrends report on Actemra

BioTrends is pleased to announce the publication of a new syndicated report, LaunchTrends®: ACTEMRA. Actemra (tocilizumab), marketed by Roche-Genentech, is the first IL-6 receptor inhibitor agent approved for rheumatoid arthritis. This report is the first in a three wave series and is derived from on-line survey responses from 77 rheumatologists and qualitative interviews with 20 rheumatologists.

19 Mar 2010

Older adult specialists travel to Haiti to render care at make-shift nursing homes

Two months after the devastating earthquake hit Haiti, the needs of older adults in the region remain an urgent priority. Dr. Martin Gorbien, a geriatrician, and Lauren Kessler, a licensed clinical social worker, both from Rush University Medical Center, will be among the first older adult specialists to travel to Haiti to provide care at make-shift nursing homes.

19 Mar 2010

Almost 62% of Canadians age 65 and older use five or more classes of prescription drugs: CIHI study

Almost two-thirds (62%) of Canadians age 65 and older living in the community in six provinces are using five or more classes of prescription drugs, according to a study released today by the Canadian Institute for Health Information.

19 Mar 2010

Survey unveils impact of gene regulation on human health

Researchers are only beginning to understand how individual variation in gene regulation can have a lasting impact on one's health and susceptibility to certain diseases. Now, an ambitious survey of the human genome has identified differences in the binding of master regulators called transcription factors to DNA that affect how genes are expressed in different people.

19 Mar 2010

Acne drug prevents HIV breakout

18 Mar 2010

New specialty service at Montefiore Medical Center helps patients with drug allergies

A Westchester patient takes aspirin for pain, but develops rashes and hives. A Bronx patient with a gastrointestinal problem caused by bacteria is prescribed penicillin, then passes out. A Bronx woman is given a contrast dye for an internal diagnostic exam, then her skin peels off.

18 Mar 2010

CytoDyn commences full humanization of Cytolin immune therapy for treating HIV/AIDS

CytoDyn, Inc. has begun full humanization of Cytolin®, the Company’s unique immune therapy for treating HIV/AIDS. Although a murine (mouse) version of Cytolin® was used for previous human experience that included some 200 patients successfully treated for up to two years, as well as an encouraging Phase I(b)/II(a) study, the Company believes that a fully-humanized version is necessary for the clinical trial that is expected to follow the current one (described at http://clinicaltrials.gov) for the reasons explained below.

17 Mar 2010

Reversal of aging in normal human cells

BioTime, Inc., a biotechnology company that develops and markets products in the field of stem cells and regenerative medicine, today announced the publication of a scientific paper titled “Spontaneous Reversal of Developmental Aging in Normal Human Cells Following Transcriptional Reprogramming.”

17 Mar 2010

Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Portola Pharmaceuticals commences Phase 1 trial of PRT062607 for chronic inflammatory diseases

ReGear Life Sciences achieves preferred partner status with Genesis Rehab Services

Walgreens's fiscal 2010 second-quarter sales up 3.1% to $17.0 billion

Dual-energy CT helps diagnose gout reliably in acute, emergency settings

Can-Fite BioPharma files patent application for treatment of Uveitis with A3 adenosine receptor ligands

ChemoCentryx undertakes Phase II clinical trial of CCX140

AARDA launches campaign on family AQ

Portable ultrasound device to treat chronic joint pain from arthritis

EUREKA project develops unique range of antibodies

Effective defense against HIV: Acne drug minocycline

Arthritis Foundation supports Congress’ efforts for meaningful health care reform

Lexicon Pharmaceuticals completes public offering and concurrent private placement of common stock

BioTrends publishes new LaunchTrends report on Actemra

Older adult specialists travel to Haiti to render care at make-shift nursing homes

Almost 62% of Canadians age 65 and older use five or more classes of prescription drugs: CIHI study

Survey unveils impact of gene regulation on human health

Acne drug prevents HIV breakout

New specialty service at Montefiore Medical Center helps patients with drug allergies

CytoDyn commences full humanization of Cytolin immune therapy for treating HIV/AIDS

Reversal of aging in normal human cells

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in